Last 13 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Meihua International Medical Technologies Co., Ltd.'s quarterly P/E stands at 1.0x, down 57.3% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 59.7% YoY to 0.6x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 0.19 | 1.01 | 0.41 | 1.39 | 1.94 | 2.38 | — | 4.57 | — | — | — | — | — |
| — | -57.3% | — | -69.7% | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.02 | 0.08 | 0.05 | 0.14 | 0.18 | 0.35 | 1.02 | 0.55 | — | — | — | — | — |
| — | -76.3% | -95.2% | -73.9% | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.01 | 0.08 | 0.06 | 0.17 | 0.24 | 0.49 | 1.43 | 0.85 | — | — | — | — | — |
| — | -84.2% | -95.5% | -79.5% | — | — | — | — | — | — | — | — | — | |
| P/FCF | 0.14 | — | 0.19 | 6.51 | 1.18 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | -0.40 | 0.62 | 0.06 | 0.79 | 1.12 | 1.53 | 19.48 | 2.63 | — | — | — | — | — |
| — | -59.7% | -99.7% | -70.1% | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | -0.41 | 0.67 | 0.06 | 0.83 | 1.16 | 1.56 | 20.17 | 2.55 | — | — | — | — | — |
| — | -57.1% | -99.7% | -67.6% | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Meihua International Medical Technologies Co., Ltd.'s operating margin was 8.5% in Q2 2025, down 7.8 pp QoQ and down 10.3 pp YoY. The trailing four-quarter average of 12.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 6.4% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 34.4% | 33.2% | 35.0% | 33.4% | 32.7% | 35.5% | 35.5% | 38.1% | 38.4% | 37.7% | 39.3% | 43.9% | 39.2% |
| — | -6.4% | -1.4% | -12.4% | -14.9% | -5.8% | -9.8% | -13.2% | -2.1% | -8.0% | — | — | — | |
| Operating Margin | 14.8% | 8.5% | 16.3% | 13.0% | 11.4% | 18.9% | 4.4% | 15.8% | 26.5% | 23.7% | 23.3% | 29.5% | 19.9% |
| — | -54.8% | +271.3% | -17.8% | -57.0% | -20.5% | -81.2% | -46.5% | +33.2% | -13.8% | — | — | — | |
| Net Margin | 11.2% | 8.3% | 11.9% | 10.4% | 9.3% | 14.7% | -0.6% | 12.0% | 21.3% | 18.8% | 19.4% | 23.5% | 15.7% |
| — | -43.5% | +1947.9% | -13.0% | -56.2% | -22.1% | -103.3% | -49.1% | +35.6% | -14.7% | — | — | — |
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.1% | 1.9% | 4.0% | 3.2% | 3.2% | 5.1% | -0.2% | 5.3% | 11.8% | 10.1% | 11.4% | 15.7% | 10.1% |
| — | -61.8% | +1886.5% | -39.6% | -72.9% | -49.9% | -101.9% | -66.5% | +16.6% | -55.7% | — | — | — | |
| ROA | 6.1% | 1.7% | 3.4% | 2.7% | 2.7% | 4.3% | -0.2% | 4.3% | 9.3% | 8.1% | 9.0% | 12.5% | 7.2% |
| — | -61.5% | +1867.8% | -38.1% | -70.6% | -46.5% | -102.1% | -65.2% | +29.4% | — | — | — | — | |
| ROIC | 7.4% | 1.6% | 4.3% | 3.2% | 3.1% | 5.5% | 1.4% | 6.0% | 11.3% | 9.9% | 11.0% | 17.4% | 9.5% |
| — | -71.7% | +211.7% | -47.3% | -72.1% | -44.5% | -87.5% | -65.5% | +19.1% | -38.3% | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Meihua International Medical Technologies Co., Ltd.'s Debt/EBITDA ratio is 3.3x, up from 0.9x last quarter — at a moderate level that warrants monitoring.
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.07 | 0.05 | 0.08 | 0.05 | 0.05 | 0.05 | 0.04 | 0.05 | 0.05 | 0.04 | 0.06 | 0.04 |
| — | +34.9% | +1.7% | +102.1% | +3.0% | -4.7% | +29.4% | -36.2% | +11.9% | — | — | — | — | |
| Debt / EBITDA | 0.53 | 3.26 | 0.91 | 1.90 | 1.27 | 0.76 | 2.98 | 0.63 | 0.34 | 0.43 | 0.29 | 0.33 | 0.37 |
| — | +326.9% | -69.3% | +203.0% | +271.3% | +76.1% | +912.7% | +92.3% | -8.2% | — | — | — | — | |
| Current Ratio | 5.26 | 5.71 | 5.26 | 4.78 | 5.27 | 5.70 | 5.60 | 5.45 | 3.24 | 3.34 | 3.17 | 2.66 | 3.88 |
| — | +0.2% | -6.0% | -12.3% | +62.9% | +70.3% | +76.6% | +105.1% | -16.6% | — | — | — | — | |
| Quick Ratio | 5.21 | 5.66 | 5.21 | 4.74 | 5.21 | 5.62 | 5.55 | 5.40 | 3.20 | 3.29 | 3.11 | 2.57 | 3.81 |
| — | +0.7% | -6.2% | -12.2% | +63.0% | +71.0% | +78.6% | +110.0% | -16.0% | — | — | — | — | |
| Interest Coverage | 9.50 | 13.19 | — | 22.79 | 22.90 | 70.53 | 22.25 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 13 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying MHUA stock.
Meihua International Medical Technologies Co., Ltd.'s current P/E is 0.2x. The average P/E over the last 4 quarters is 1.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Meihua International Medical Technologies Co., Ltd.'s current operating margin is 14.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Meihua International Medical Technologies Co., Ltd.'s business trajectory between earnings reports.